bitolterol (Tornalate)

03/01/1994 - "This open-label, placebo-controlled study was undertaken to assess the safety and effectiveness of bitolterol mesylate in pediatric asthma patients. "
03/01/1994 - "We conclude that doses of 1.0 and 1.5 mg bitolterol mesylate administered by continuous-flow nebulization are safe, effective, and well-tolerated for the treatment of asthma in pediatric patients."
01/01/1996 - "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma."
03/01/1994 - "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma."
01/01/1988 - "Preliminary therapeutic trials of bitolterol administered by aerosol or nebuliser in adult patients with asthma have shown variable but significant improvements in forced expiratory volume in 1 second (FEV1) and a duration of action of up to 8 hours in some patients. "

09/01/1984 - "This study indicates that bitolterol is more effective than isoproterenol in degree and duration of bronchodilatation in patients with advanced chronic obstructive pulmonary disease."
09/01/1984 - "Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease."
05/01/1985 - "In preclinical and clinical studies to date, bitolterol has proved to be an effective bronchodilator for adult and pediatric patients with chronic stable asthma and for some with chronic obstructive pulmonary disease. "

05/01/1995 - "The results of this retrospective study suggest that bitolterol is an effective and safe treatment in patients with conditions associated with reversible bronchospasm."
05/01/1995 - "Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm."
05/01/1995 - "In this retrospective study of 24 older patients with a variety of conditions associated with reversible bronchospasm--asthma, asthma with emphysema, chronic bronchitis, and asthmatic bronchitis--symptomatic improvement was noted after treatment with inhaled bitolterol mesylate. "

01/01/1986 - "Bitolterol mesylate in exercise-induced asthma."
01/01/1986 - "Bitolterol mesylate aerosol was very effective in protecting against exercise-induced asthma. "
01/01/1986 - "Twelve subjects with exercise-induced asthma performed cycloergometer exercise 45 minutes after three inhalations of bitolterol mesylate aerosol (1050 micrograms), or isoproterenol (255 micrograms), or placebo in random sequence. "
01/01/1986 - "The main objective of this double-blind, crossover study was to determine the effect of the aerosolized beta-adrenergic agent, bitolterol mesylate, on exercise-induced asthma while its efficacy was being compared with isoproterenol and placebo. "

05/01/1985 - "There is no evidence for cardiotoxicity when bitolterol is used in combination with theophylline in human studies. "
01/01/1984 - "This study had three major objectives: first, to evaluate the efficacy and safety of a new long-acting beta 2-agonist, bitolterol mesylate, given as metered-dose aerosol in a regular "round-the-clock" asthma medication regimen; second, to compare the efficacy and safety of bitolterol with those of sustained-release theophylline alone and of the combination of bitolterol and theophylline; third, to use 24 hr Holter monitoring to evaluate cardiac toxicity of the three medication regimens. "